Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/CD18 (αMβ2; CR3; Mac-1). Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes.
Leukadherin-1 (1 mg/kg; i.p.; twice daily for 14 days) is beneficial in preventing hyperoxia-induced neonatal lung injury, an experimental model of bronchopulmonary dysplasia (BPD).